Cargando…

Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics

BACKGROUND: The biology of small cell ovarian carcinoma of the hypercalcemic type (SCCOHT), which is a rare and aggressive form of ovarian cancer, is poorly understood. Tumourigenicity, in vitro growth characteristics, genetic and genomic anomalies, and sensitivity to standard and novel chemotherape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gamwell, Lisa F, Gambaro, Karen, Merziotis, Maria, Crane, Colleen, Arcand, Suzanna L, Bourada, Valerie, Davis, Christopher, Squire, Jeremy A, Huntsman, David G, Tonin, Patricia N, Vanderhyden, Barbara C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635907/ https://www.ncbi.nlm.nih.gov/pubmed/23433318 http://dx.doi.org/10.1186/1750-1172-8-33

Ejemplares similares

Technical challenges and limitations of current mouse models of ovarian cancer
por: Garson, Kenneth, et al.
Publicado: (2012)

The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome
por: Wojnarowicz, Paulina M., et al.
Publicado: (2012)

Transcriptional heterogeneity of stemness phenotypes in the ovarian epithelium
por: Carter, Lauren E., et al.
Publicado: (2021)

Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease
por: Fleury, Hubert, et al.
Publicado: (2015)

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population
por: Belanger, Moria H, et al.
Publicado: (2015)

Characterization of three new serous epithelial ovarian cancer cell lines
por: Ouellet, Véronique, et al.
Publicado: (2008)

Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours
por: Birch, Ashley H., et al.
Publicado: (2011)

Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families
por: Oros, Kathleen K, et al.
Publicado: (2006)

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
por: McCloskey, Curtis W., et al.
Publicado: (2018)

A New Spontaneously Transformed Syngeneic Model of High-Grade Serous Ovarian Cancer with a Tumor-Initiating Cell Population
por: McCloskey, Curtis W., et al.
Publicado: (2014)

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent
por: Cavallone, Luca, et al.
Publicado: (2008)

The chemiluminescence based Ziplex(® )automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip(® )expression profiles
por: Quinn, Michael CJ, et al.
Publicado: (2009)

The significance of ovarian fibrosis
por: Landry, David A., et al.
Publicado: (2020)

Germline TP53 mutational spectrum in French Canadians with breast cancer
por: Arcand, Suzanna L, et al.
Publicado: (2015)

Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer
por: Létourneau, Isabelle J, et al.
Publicado: (2012)

Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome
por: Gambaro, Karen, et al.
Publicado: (2015)

Animal models of ovarian cancer
por: Vanderhyden, Barbara C, et al.
Publicado: (2003)

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers
por: Le Page, Cécile, et al.
Publicado: (2018)

Targeting TBP-Associated Factors in Ovarian Cancer
por: Ribeiro, Jennifer R., et al.
Publicado: (2014)

Investigating the causal role of MRE11A p.E506* in breast and ovarian cancer
por: Elkholi, Islam E., et al.
Publicado: (2021)

PAX2 induces vascular-like structures in normal ovarian cells and ovarian cancer
por: Alwosaibai, Kholoud, et al.
Publicado: (2022)

17β-Estradiol sensitizes ovarian surface epithelium to transformation by suppressing Disabled-2 expression
por: Vuong, Nhung H., et al.
Publicado: (2017)

Exploring the invisible: art, science, and the spiritual
por: Gamwell, Lynn
Publicado: (2020)

Mathematics and art: a cultural history
por: Gamwell, Lynn
Publicado: (2016)

Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity
por: Wojnarowicz, P, et al.
Publicado: (2012)

The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy
por: Rodriguez, Galaxia M., et al.
Publicado: (2018)

Non-canonical WNT5a regulates Epithelial-to-Mesenchymal Transition in the mouse ovarian surface epithelium
por: Abedini, Atefeh, et al.
Publicado: (2020)

The Importance of a Late First Trimester Placental Sonogram in Patients at Risk of Abnormal Placentation
por: Moretti, Felipe, et al.
Publicado: (2014)

17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo
por: Laviolette, Laura A, et al.
Publicado: (2014)

GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer
por: Hodgkinson, Kendra, et al.
Publicado: (2018)

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer
por: Koti, Madhuri, et al.
Publicado: (2013)

The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population
por: Alenezi, Wejdan M., et al.
Publicado: (2022)

An Immunohistochemical Algorithm for Ovarian Carcinoma Typing
por: Köbel, Martin, et al.
Publicado: (2016)

A genome-wide strategy to identify causes and consequences of retrotransposon expression finds activation by BRCA1 in ovarian cancer
por: Alkailani, Maisa, et al.
Publicado: (2021)

The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression
por: Sheta, Razan, et al.
Publicado: (2019)

Kallikreins 5, 6 and 10 Differentially Alter Pathophysiology and Overall Survival in an Ovarian Cancer Xenograft Model
por: Pépin, David, et al.
Publicado: (2011)

PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming
por: Feng, Yan, et al.
Publicado: (2020)

The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool for Ovarian Cancer Immunotherapy Research
por: Rodriguez, Galaxia M., et al.
Publicado: (2022)

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
por: Farokhi Boroujeni, Salar, et al.
Publicado: (2023)

Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers
por: Alenezi, Wejdan M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_drsi61md2effevie6bfvoc8gnm